奥希替尼治疗EGFR突变阳性非小细胞肺癌的疗效及对患者外周血CTC、VEGF、CA125表达的影响

目的 探究奥希替尼治疗表皮生长因子(EGFR)突变阳性非小细胞肺癌(NSCLC)的疗效、不良反应及对患者外周血循环肿瘤细胞(CTC)、血管内皮生长因子(VEGF)、糖类抗原125(CA125)表达的影响.方法 以83例EG-FR突变阳性NSCLC患者为研究对象,根据化疗方法不同将其分为观察组(奥希替尼治疗,41例)和对...

Curative Effect of Osimertinib on Non-small Cell Lung Cancer with EGFR Mutation-positive and Its Influences on Peripheral Blood CTC,VEGF and CA125

Objective To explore the effect and adverse reactions of osimertinib in the treatment of non-small cell lung cancer(NSCLC) with epidermal growth factor receptor(EGFR) mutation-positive, as well as its influences on peripheral blood circulating tumor cells(CTC),vascular endothelial growth factor(VEGF) and carbohydrate antigen 125(CA125).Methods A total of 83 patients with EGFR mutation-positive NSCL were enrolled as the research objects.According to different chemotherapy methods, they were divided into the observation group(osimertinib, 41 cases) and the control group(cisplatin preparation chemotherapy, 42 cases).All were followed up for 1 year after treatment.The clinical curative effect and prognosis were compared between the 2 groups.The expressions of peripheral blood CTC,VEGF and CA125 in both groups were observed before and after treatment.The occurrence of toxic reactions during chemotherapy in both groups was statistically analyzed.Results The disease control rate in the observation group was higher than that in the control group(P<0.05).After treatment, levels of peripheral blood CTC,VEGF and CA125 in the observation group were lower than those in the control group, while FEV1 and FEV1/FVC were greater than those in the control group(P<0.05).After treatment, scores of physiological status, functional status and additional attention in the observation group were higher than those in the control group(P<0.05).After treatment, 1-year survival rate in the observation group was higher than that in the control group, and the incidence of thrombocytopenia during treatment was lower than that in the control group(P<0.05).Conclusion The curative effect of osimertinib is good on EGFR mutation-positive NSCLC.It can reduce peripheral blood CTC,inhibit the expressions of VEGF and CA125,reduce toxic reactions and improve quality of life.